Latest Publications & News

A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids.  Jan Wysocki, Minghao Ye, Luise Hassler, Ashwani Kumar Gupta, Yuguo Wang, Vlad Nicoleascu, Glenn Randall, Jason A. Wertheim and Daniel Batlle. JASN February 2021, ASN.2020101537; DOI.   

Davidson AM, Wysocki J, Batlle D. Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor: Therapeutic Implications. Hypertension. 2020 Nov;76(5):1339-1349. doi: 10.1161/HYPERTENSIONAHA.120.15256. Epub 2020 Aug 27. PubMed PMID: 32851855; PubMed Central PMCID: PMC7480804.

Wysocki J, Schulze A, Batlle D. Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. Biomolecules. 2019 Dec 17;9(12). doi: 10.3390/biom9120886. PubMed PMID: 31861139; PubMed Central PMCID: PMC6995632.

Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clin Sci (Lond). 2020 Mar 13;134(5):543-545. doi: 10.1042/CS20200163. PubMed PMID: 32167153.

Marquez A, Wysocki J, Pandit J, Batlle D. An update on ACE2 amplification and its therapeutic potential. Acta Physiol (Oxf). 2020 May 29;:e13513. doi: 10.1111/apha.13513. [Epub ahead of print] Review. PubMed PMID: 32469114; PubMed Central PMCID: PMC7267104.

Wysocki J, Lores E, Ye M, Soler MJ, Batlle D. Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. J Am Soc Nephrol. 2020 Sep;31(9):1941-1943. doi: 10.1681/ASN.2020050667. Epub 2020 Jul 15. PubMed PMID: 32669323; PubMed Central PMCID: PMC7461678.